Skip to main content

Autoimmune & autoinflammatory

Autoimmune haemolytic anaemia

In autoimmune haemolytic anaemia the immune system destroys its own red cells faster than the marrow can replace them - warm and cold forms differ fundamentally, and both are very treatable.

Key points

The essentials at a glance.

What to look out for, which tests matter, who treats it, and what usually happens next.

  • Symptoms: fatigue, breathlessness, pallor and jaundice, sometimes with dark urine - developing over days or weeks

  • The direct antiglobulin (Coombs) test is the pivotal investigation, positive in the overwhelming majority

  • Warm AIHA (IgG-mediated) is treated with steroids and rituximab; cold agglutinin disease needs cold avoidance and B-cell-directed therapy - steroids work poorly

  • Half of cases are secondary: lymphoma, CLL, lupus, infections and certain drugs must be sought

  • Folic acid supports the overworked marrow; transfusion is safe when needed despite cross-matching difficulty

Understanding it

About Autoimmune haemolytic anaemia.

The laboratory picture tells the story before any specialist arrives: anaemia with raised reticulocytes as the marrow sprints, raised bilirubin and LDH with low haptoglobin as red cells lyse, and a positive Coombs test proving antibody on the cell surface. The temperature split then directs everything - warm antibodies coat cells for splenic destruction and respond to immunosuppression, while cold agglutinins clump cells in the chilled circulation of fingers, nose and ears, fix complement, and laugh at prednisolone - a distinction some general clinicians still miss at real cost to patients.

Warm AIHA management has modernised: prednisolone remains the opener, but early rituximab has strong trial support and splenectomy has retreated down the ladder; cold agglutinin disease centres on thermal protection and rituximab-based or complement-directed therapy, with the newer agent sutimlimab specifically licensed in some jurisdictions. Because half of cases shadow another disease - lymphoproliferative above all - CT imaging, flow cytometry and autoimmune serology belong in every new diagnosis, and relapse surveillance continues long after remission. In many parts of the UK, a routine NHS referral to the relevant specialist clinic currently means waiting many months - sometimes more than a year for the rarest conditions - whereas an initial appointment with a private consultant is typically available within around two weeks, with investigations arranged soon after.

Frequently asked

Common questions about Autoimmune haemolytic anaemia.

Quick, plain-English answers to what people ask us most.

  • What is autoimmune haemolytic anaemia?

    Autoimmune haemolytic anaemia is a recognised medical condition that can affect people in different ways, ranging from mild and easily managed to more significant, depending on the underlying cause, how early it is picked up, and how it is treated. Getting a clear diagnosis is usually the first step towards the right management plan.

  • What causes autoimmune haemolytic anaemia?

    Autoimmune haemolytic anaemia can arise from a combination of factors, which may include genetics, lifestyle, environmental exposures, other underlying health conditions, or simply the normal effects of ageing on the body. In many cases no single cause is found, and several factors act together. A clinician can help identify which factors are most relevant in an individual case.

  • What are the symptoms of autoimmune haemolytic anaemia?

    Symptoms of autoimmune haemolytic anaemia vary from person to person and depend on how severe the condition is and which structures are affected. Some people notice symptoms gradually over weeks or months, while others experience a more sudden onset. Because symptoms can overlap with other conditions, a proper assessment is important to reach an accurate diagnosis rather than relying on symptoms alone.

  • Is autoimmune haemolytic anaemia serious or dangerous?

    Most cases of autoimmune haemolytic anaemia are manageable, especially when identified and treated early, but severity varies from mild and self-limiting to more significant, depending on individual circumstances. Left unassessed, some cases can lead to complications or a longer-term impact on daily life. If you are worried about your symptoms, it is always worth getting them checked rather than waiting.

  • Is autoimmune haemolytic anaemia hereditary or genetic?

    Some cases of autoimmune haemolytic anaemia have a genetic component and can run in families, while others occur without any family history at all. Having a relative with the condition may modestly increase your own risk, but it does not mean you will definitely develop it yourself. If you are concerned about a family history, mention this to your doctor, as it may occasionally influence screening or monitoring.

  • Can autoimmune haemolytic anaemia be cured, reversed or prevented?

    Outlook varies with autoimmune haemolytic anaemia: some cases resolve completely with treatment, others improve significantly but need ongoing management, and a smaller number become a long-term condition to be controlled rather than cured. Prevention strategies, such as addressing modifiable risk factors, can reduce your chances of developing it or of it recurring, but cannot guarantee against it in every case.

  • How is autoimmune haemolytic anaemia treated?

    Treatment for autoimmune haemolytic anaemia is tailored to the individual and depends on severity, underlying cause and personal circumstances. Options can range from simple lifestyle measures, monitoring and conservative treatment through to medication, specialist procedures or surgery in more significant cases. A specialist assessment helps identify which combination of treatments is most appropriate for you.

  • How long does autoimmune haemolytic anaemia last?

    The duration of autoimmune haemolytic anaemia varies considerably: some people recover within days or weeks, while others live with a more persistent or recurring condition that needs ongoing management. Response to treatment, how early it is started, and individual factors all influence the timescale. Your clinician can give you a more personalised estimate once your specific circumstances are known.

  • When is surgery needed for autoimmune haemolytic anaemia?

    Surgery is not usually the first option for autoimmune haemolytic anaemia and is generally reserved for cases where conservative treatment has not worked, symptoms are severe, or there is a significant structural problem that needs to be corrected directly. The decision depends on your specific findings, symptoms and how they are affecting your life. A specialist consultation is the best way to establish whether surgery is being considered too early, or should be considered sooner rather than later.

  • When should I see a doctor about autoimmune haemolytic anaemia, and how quickly can I be seen privately?

    It is worth seeing a doctor about autoimmune haemolytic anaemia if symptoms are persistent, getting worse, or affecting your daily life, rather than waiting to see if they settle on their own. NHS routine referrals to a specialist can currently take anywhere from around 20 to 45 weeks or more depending on your area, whereas a private consultant can typically see you within about 2 weeks. Getting an earlier assessment can help clarify the diagnosis and start the right treatment sooner.